TECX

Tectonic

--(--)

Market Open: --

--(--)

Post-Market: --

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About TECX

Tectonic Therapeutic, Inc.

A clinical stage biotechnology company focused on developing G protein coupled receptor (GPCR) targeted therapeutic proteins

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

06/21/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.tectonictx.com

Security Type

Common stock

Office address

490 Arsenal Way, Suite 210, Watertown, MA 02472

Business

Introduction

Tectonic Therapeutic, Inc., is a corporation organized under the laws of the State of Delaware. The Company is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that regulate the activity of G protein-coupled receptors (" GPCRs "). Leveraging its proprietary technology platform called GEODe (" GPCR Engineered for Optimal Discovery "), Tectonic focuses on developing biopharmaceuticals to overcome existing challenges of GPCR-targeted drug discovery and harness the human body to change the course of disease. Tectonic focuses on areas with significant unmet medical needs, which are often areas with poor or non-existent treatment options, because new drugs in these areas have the potential to improve the quality of life of patients.

Company Financials

EPS

TECX has released its 2024 Q4 earnings. EPS was reported at -0.84, versus the expected -0.92, beating expectations. The chart below visualizes how TECX has performed over recent quarters, highlighting trends in earnings surprises.